InvestorsHub Logo
icon url

kabunushi

10/07/20 12:40 PM

#315063 RE: exwannabe #315049

They raised how much was it, $11M or $12M in the Sept Q? How much of that will show up on the balance sheet as Sawston assets? Care to guess? Not sure how much will show up as of 9/30 and how much we will have to wait till the year end balance sheet to see as the construction continues into this Q.
icon url

hyperopia

10/07/20 8:53 PM

#315181 RE: exwannabe #315049

ex, it’s clear that the Sawston facility is at least six months behind, at least partially due to COVID. You know guidance wasn’t given, but there was a clue in the last 10-Q:

Advent BioServices Agreement
The Company has a Manufacturing Services Agreement with Advent BioServices for manufacture of DCVax-L products at an existing facility in London, as previously reported.  The Company also has an Ancillary Services Agreement with Advent, which establishes a structure under which Advent will submit Statements of Work (“SOWs”) for activities related to the development of the Sawston facility and the compassionate use activities in the UK, as previously reported.  To date, Advent has not yet submitted SOWs and the Company has not yet made any payments for these Ancillary Services. The Ancillary Services Agreement had an original term of 8 months, ended in July 2020. On August 7, 2020, the Company extended the term by 12 months, and did not make any other changes.